by Dan Stanton
Fully closed and automated platforms are key to reducing the current high costs of cell and gene therapy manufacturing, say industry experts.
Cell and gene therapies (CGTs) have come a long way over the past two years, …
by Dan Stanton
This is the first time in history that we can make more effective medicines than we can afford, says Dark Horse Consulting.
The Phacilitate conference took place in Miami this week, and in the plenary session Anthony …
by Dan Stanton
The US FDA predicts it will receive more than 200 regenerative INDs per year from 2020 and will add 50 additional staff to review these products.
There has been “a large upswing in the number of investigational …
by Katy Spink & Andrew Steinsapir
With the 2017 FDA approvals and launches of the first gene-modified cell and pure-play gene therapy products to gain licensure in the United States, increasing attention has been paid to the high cost of …
Experts from North American and European organisations are also supporting the trade mission. Anthony Davies, Ph.D., CEO of Dark Horse Consulting added, “As the first and only global consulting practice focused on CMC for cell and gene therapy, Dark Horse …
